首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Synthesis and pharmacological evaluation of bivalent antagonists of the nociceptin opioid receptor.
【24h】

Synthesis and pharmacological evaluation of bivalent antagonists of the nociceptin opioid receptor.

机译:伤害感受肽阿片受体的二价拮抗剂的合成和药理评价。

获取原文
获取原文并翻译 | 示例
           

摘要

Bivalent ligands constituted by two identical pharmacophores structurally related to the Nociceptin Opioid Receptor (NOPr) antagonist JTC-801 were synthesized and their binding affinities for NOPr were evaluated. The novel ligands are formed by two modified JTC-801 units linked by di-iminic and di-aminic spacers with length ranging from three to ten methylene units. Moreover, the synthesis and the pharmacological characterization were extended to the corresponding univalent ligands. The latter compounds consisted in a single modified JTC-801 unit and an alkyl or alkylamino or alkylimino tail. The purpose of this study is to feature the location and surroundings of the allosteric binding site(s) of pharmacophores containing the 4-aminoquinoline structure. Most important, the bivalent ligands were exploited to reveal the eventual occurrence of a supramolecular receptorial architecture of the NOPr. All the bivalent derivatives 4 and 5 proved to be active in the nanomolar range with no outstanding dependence on the chain length. They showed potencies from three to ten times higher than the corresponding monomers. Consequently, results clearly indicated a positive role of the second pharmacophore in the ligand-protein interaction. The pharmacological profile of the monomers 7 and 8 clarified the contribution of the linker chain to NOP receptor affinity and suggested the presence of a lipophilic acidic site neighbouring the binding site of the JTC-like ligands. Selectivity of saturated compounds 5, 7, and 8 was tested by binding experiments on delta, kappa and mu opioid receptors. Results indicated a general loss of selectivity as compared to JTC-801. In the [(35)S]GTPgammaS binding assay, all the compounds revealed antagonistic properties at the NOP Receptor. In conclusion the present study set the basis for a systematic investigation on the structural modifications that can be introduced into novel ligands for NOPr and helped to feature the surrounds of the allosteric site of NOPr.
机译:合成了由与Nociceptin阿片受体(NOPr)拮抗剂JTC-801结构相关的两个相同药效基团构成的二价配体,并评估了它们对NOPr的结合亲和力。新型配体由两个修饰的JTC-801单元形成,这些单元通过二亚氨基和二氨基间隔基连接,长度范围为3至10个亚甲基单元。此外,合成和药理学表征扩展到相应的单价配体。后面的化合物由单个修饰的JTC-801单元和烷基或烷基氨基或烷基亚氨基尾组成。这项研究的目的是确定含有4-氨基喹啉结构的药效基团的变构结合位点的位置和周围环境。最重要的是,利用二价配体揭示了NOPr超分子受体结构的最终出现。事实证明,所有二价衍生物4和5在纳摩尔范围内均具有活性,并且对链长没有明显的依赖性。他们显示出比相应单体高三至十倍的效力。因此,结果清楚地表明第二药效团在配体-蛋白质相互作用中的积极作用。单体7和8的药理学特征阐明了连接链对NOP受体亲和力的贡献,并表明在JTC样配体的结合位点附近存在亲脂性酸性位点。通过对δ,κ和μ阿片样物质受体的结合实验来测试饱和化合物5、7和8的选择性。结果表明,与JTC-801相比,选择性普遍下降。在[(35)S] GTPgammaS结合测定中,所有化合物均在NOP受体处显示出拮抗特性。总而言之,本研究为系统研究可引入NOPr的新型配体的结构修饰奠定了基础,并有助于表征NOPr的变构位点周围。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号